Gut Microbiome Composition Predicts Severe COVID-19 Hospitalization and Mortality
Overview
In a large population-based cohort, gut microbiota composition was linked to the risk of future severe COVID-19 outcomes. Specifically, higher abundances of butyrate-producing bacteria were associated with a lower risk of COVID-19 hospitalization and mortality.
Background
Gut microbiota disruptions, particularly loss of anaerobic butyrate-producing bacteria, have been observed in hospitalized COVID-19 patients. It remains unclear whether these changes are a consequence of infection or contribute to susceptibility. Preclinical studies suggest butyrate enhances immune defenses against viral pneumonia. This study investigates if gut microbiota composition precedes and predicts severe COVID-19 in humans.
Data Highlights
Parameter
Finding
Participants with gut microbiota sequenced
5084
Severe COVID-19 cases (hospitalization or mortality)
73
Association of butyrate-producing bacteria with severe COVID-19 risk
Higher abundance linked to lower risk (significant in continuous and tertile analyses)
Gut microbiota diversity
Higher diversity associated with reduced risk, but not significant after adjustment
Gut microbiota composition differs significantly between individuals who develop severe COVID-19 and those who do not.
Increased relative abundance of butyrate-producing bacteria correlates with a reduced risk of COVID-19 hospitalization and mortality.
Higher gut microbiota diversity is associated with lower severe COVID-19 risk, though this association is not significant after adjusting for confounders.
Enterocloster genus abundance is linked to increased risk of severe COVID-19.
Members of the Oscillospirales order, known butyrate producers, are associated with decreased risk of severe COVID-19.
Clinical Implications
Assessment of gut microbiota composition, particularly butyrate-producing bacteria levels, may help identify individuals at higher risk for severe COVID-19. Interventions aimed at preserving or restoring butyrate-producing gut bacteria could represent a novel preventive strategy against severe COVID-19 outcomes. These findings support further exploration of microbiome-targeted therapies in COVID-19 management.
Conclusion
Gut microbiota alterations, especially reduced butyrate-producing bacteria, precede severe COVID-19 and may influence susceptibility to hospitalization and mortality. Targeting the gut microbiome offers a promising avenue for COVID-19 prevention.
References
HELIUS Study Group/2024 -- Gut Microbiome Composition as a Predictor of Future Hospitalization and Mortality Due to COVID-19
Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.
